African Union says urgent need to address patents and technology barriers for access to future COVID-19 vaccines
AIDS related mortality remains high - 770,000 deaths in 2018 - and has hardly declined in recent years. This global trend is reflected in countries where Médecins sans Frontières (MSF) works and continues to witness high ongoing mortality.
To achieve the UNAIDS target of 500,000 deaths in 2020 requires a focus on and a drastic acceleration of measures to decrease mortality. For this it is necessary to plan, fund and implement a package of care to prevent, detect and treat Advanced HIV Disease (AHD) or AIDS, as outlined in the World Health Organisation’s 2017 Guidelines for managing Advanced HIV Disease and rapid initiation of antiretroviral therapy.
This report, compiled by MSF, presents data from the AHD dashboard initiated by the HIV Advanced Disease Consortium (HIV-ADC).
NO TIME TO LOSE: DETECT, TREAT AND PREVENT AIDS
Read, watch, shareNo time to lose: detect, treat and prevent AIDS > Paragraphs
In 2011, UNAIDS launched the “Global Plan Towards the Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive”, endorsed by UN member-state governments to scale up prevention of mother-to-child transmission (PMTCT) services. While this initiative saw the number of new HIV infections in children fall from 280,000 in 2010 to 160,000 in 2018, the rate of decline in the past 3-4 years has plateaued, leaving the goal of only 20,000 new infections per year by 2020 far out of reach. Nine out of 10 of these children live in sub-Saharan Africa. In 2018, 82% of pregnant women living with HIV globally were receiving antiretroviral therapy (ART), but wide regional variations exist, and access to ART for PMTCT ranges from 92% in eastern and southern Africa, to 53% in the Middle East and North Africa. ART coverage for children living with HIV continues to lag behind – in 2018, more than half of children (54%) were still not receiving the lifesaving treatment they needed.
This report examines the barriers to preventing new paediatric HIV infections and to providing timely and optimal treatment where we have failed to prevent transmission.